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Abstract
The water channel aquaporin-1 (AQP1) is the molecular
counterpart of the ultrasmall pore that mediates free water
transport during peritoneal dialysis (PD). Proof-of-princi-
ple studies performed in rats have shown that treatment
with corticosteroids upregulates the expression of AQP1
in the peritoneal capillaries, causing a significant increase
in free water transport. Whether such a beneficial effect
could be observed in end-stage renal disease patients trea-
ted by PD remains unknown. Peritoneal transport parame-
ters were evaluated in three patients on PD, shortly before
and after living-donor renal transplantation and treatment
with high-dose methylprednisolone (1.0–1.2 g/m2). As
compared with pre-transplantation values, the post-trans-
plantation test revealed an ~2-fold increase in the sodium
sieving and ultrasmall pore ultrafiltration volume, suggest-
ing an effect on AQP1 water channels. In contrast, there
was no change in the parameters of small solute transport.
The direct involvement of AQP1 in these changes is sug-
gested by the expression of glucocorticoid receptors in the
human peritoneum and the presence of conserved gluco-
corticoid response elements in the promoter of the human
AQP1 gene.
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Introduction
The capacity for ultrafiltration (UF) across the peritoneal
membrane is a major predictor of outcome and mortality for
end-stage renal disease (ESRD) patients treated with perito-
neal dialysis (PD) [1, 2]. The major barrier for the transport of
water and solutes across the peritoneal membrane is the
4142
 The Author 2011. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
For Permissions, please e-mail: journals.permissions@oup.com
endothelium lining peritoneal capillaries. Modelling of peri-
toneal transport has predicted that endothelial cells contain
ultrasmall pores (radius < 3 Å) that facilitate the osmotic
transport of water during a hypertonic dwell [3]. The ultra-
small pores account for half of the UF and their patency
explains the ‘sodium sieving’, i.e. the marked fall of the dial-
ysate to plasma ratio of sodium during the first hour of PD [3].
Several lines of evidence have demonstrated that the water
channel aquaporin-1 (AQP1), which is abundantly expressed
in the endothelial cells lining peritoneal capillaries and vei-
nules [4], is the molecular counterpart of the ultrasmall pores
([5], for review). Studies in Aqp1-null mice demonstrated that
AQP1 facilitates water transport and mediates approximately
half of the UF during crystalloid osmosis [6, 7]. Accordingly,
increasing the expression of AQP1 in the peritoneum could
improve water transport in PD patients. Based on the presence
of glucocorticoid response elements (GREs) in the promoter
of the murine AQP1 gene [8], Stoenoiu et al. [9] demonstrated
that treatment with corticosteroids increases the expression of
AQP1 in peritoneal capillaries, mirrored by increased water
transport and UF, without affecting the transport of small
solutes. Thus far, it is unknown whether a similar effect could
be evidenced in patients undergoing PD. We report the serial
determination of water and solute transport parameters across
the peritoneal membrane in three PD patients that received
high-dose glucocorticoids as standard care after a living-donor
renal transplantation.
Materials and methods
The clinical features of the three PD patients are detailed in Table 1. ‘Patient
1’ is an 11-year-old girl who presented haemolytic uraemic syndrome at 18
months of age, progressing to ESRD at the age of 10 years. She was initially
treated by continuous ambulatory peritoneal dialysis (CAPD) for 6 months,
followed by automated peritoneal dialysis for 4 months. ‘Patient 2’ is a 54-
year-old male with autosomal dominant polycystic kidney disease progress-
ing to ESRD at the age of 52 years. He was treated by CAPD for 9 months
before transplantation. ‘Patient 3’ is a 6-year-old boy who reached ESRD at
the age of 5 years for congenital vesico-ureteral reflux. He was treated by
CAPD for 5 months. The course of PD was uncomplicated in the three
patients. They underwent a living-donor renal transplantation after a mean
of 8 months (range: 5–10 months) of PD. The renal transplantation was
uneventful, with immediate graft function in the three cases. The details of
cumulative methylprednisolone dose and immunosuppressive treatment are
given in Table 1. The peritoneal function was assessed in the three patients
using the mini peritoneal equilibration testing (mini-PET) [10] performed
before (range: 1 day to 3 months) and after (range: 7–39 days) renal trans-
plantation. The sodium concentration was measured by indirect ion-selective
analysis (Modular Analytics Evo 900, calibrated by ISE compensator;
Roche Diagnostics, Buenos Aires, Argentina). The study was approved by
the Ethical Review Board and informed consent was obtained.
The expression of the glucocorticoid receptor (GR) messenger RNA was
assessed in human peritoneal biopsies using reverse transcription–polymer-
ase chain reaction (RT–PCR) [9]. Total RNA was extracted from two human
peritoneal biopsies (obtained at time of catheter removal in PD patients, ref.
[4]) using Aurum Total RNA Tissue Kit (Bio-Rad, Hercules, CA), follow-
ing the manufacturer’s protocol, followed by DNAse I treatment to eliminate
genomic DNA contamination. Total RNA was extracted from human eryth-
roleukemia cells (positive control for GR expression) using RNAqueous-
Micro kit (Ambion). One microgram of RNA was used to perform the
reverse transcriptase reaction with iScript cDNA Synthesis Kit (Bio-
Rad). RT–PCR detection was performed with FastStart Taq DNA Polymer-
ase (Roche) for 32 cycles, and polymerase chain reaction products visualized
on a 1.5% agarose gel with GelRed dye (Sigma). The primers were designed
using Beacon Design 2.0 (Premier Biosoft International, Palo Alto, CA):
glyceraldehyde 3-phosphate dehydrogenase (forward 5#-3#: GGG GCT
CTC CAG AAC ATC AT and reverse 5#-3#: TCT AGA CGG CAG
GTC AGG T) and GR (forward 5#-3#: ACA CTG CCC CAA GTG AAA
AC and reverse 5#-3#: CCA TGA ACA GAA ATG GCA GA).
Immunostaining was performed on paraffin-embedded sections of human
peritoneal biopsies by using a sequential staining protocol [4]. Sections were
Table 1. Clinical and peritoneal equilibration test (mini-PET) parameters in the three patientsa
Patient 1 Patient 2 Patient 3
Gender, age (years) Female, 11 Male, 54 Male, 6
Cause of ESRD Haemolytic
uraemic syndrome
ADPKD Congenital reflux
Age at ESRD (years) 10 52 5
Duration of PD (months), modality 10, CAPD (6) then APD (4) 9, CAPD 5, CAPD
Residual diuresis on PD (mL/day) 500 1000 500
Time of pre-transplant mini-PET (days) 1 day 90 days 2 days
Methylprednisolone dose (g/m2)b 1.0 1.0 1.2
Other (immunosuppressive)
drugs introduced
per transplantation
Daclizumab (1 mg/kg);
tacrolimus (0.15 mg/kg/day);
MMF (1 g/day)
Tacrolimus (0.15 mg/kg/day);
MMF (2 g/day)
Daclizumab (1 mg/kg);
tacrolimus (0.15 mg/kg/day);
MMF (1 g/day)
Time to post-transplant
mini-PET (days)
7 20 39
Serum creatinine at post-transplant
(mg/dL)
0.44 1.2 0.43
mini PET Pre-TP Post-TP Pre-TP Post-TP Pre-TP Post-TP
Sodium sieving (%)c 8.3 11.4 5.4 13.1 4.4 12.7
Sodium dip (mmol/L)d 11 15 7 17 6 17
UF USP (mL) 126 150 170 332 30 90
UF 1 h (mL) 240 180 620 380 60 180
D/P creatinine 0.40 0.47 0.54 0.46 0.66 0.66
Volume infused (L/m2) 1.1 1.1 1.2 1.2 0.9 0.9
aESRD, end-stage renal disease; APD, automated peritoneal dialysis; MMF, mycophenolate mofetil; PET, peritoneal equilibration test. D/P, dialysate-
over-plasma ratio; Post-TP, post-transplantation; Pre-TP, pre-transplantation; USP, ultrasmall pores.
bCumulative dose until post-transplantation mini-PET.
cSodium sieving: (D0/P0 – D60/P60)/D0/P0 3 100 (in %) (ref. [7]).
dSodium dip: absolute dip of dialysate sodium concentration at 60 min of the PET (mmol/L) [( ref. 11)].
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incubated with 3% serum for 20 min before adding anti-von Willebrand
factor (DAKO, Glostrup, Denmark) diluted in phosphate-buffered saline con-
taining 2% bovine serum albumin for 1 h. After washing, sections were
incubated with Alexa633-labelled secondary anti-IgG antibodies (Invitrogen,
Carlsbad, Belgium) for 45 min. The secondary staining was performed by
adding anti-glucocorticoid receptor (Abcam, Cambridge, UK) and labeled
with Alexa488-labeled secondary anti-IgG antibodies before mounting in
Prolong Gold Anti-fade reagent (Invitrogen). Sections were viewed under a
Zeiss LSM510Meta Confocal microscope (Carl Zeiss, Zaventem, Belgium),
using 320 Plan-Apochromat or 363/1.4 Plan-Apochromat oil-immersion
objectives (Zeiss).
The 3-kb promoter sequence of the human AQP1 gene was analysed
for putative GRE using Transcription Element Search Software (http://
www.cbil.upenn.edu/cgi-bin/tess/tess).
Fig. 1. Transport parameters before and after renal transplantation and expression of the GR in the human peritoneum. (A) Comparison of the transport
parameters before and after renal transplantation. A mini-PET was performed before and after transplantation in the three patients, who received
methylprednisolone at time of transplantation. As compared with baseline values, the three patients show an ~2-fold increase in the sodium sieving
and in the ultrasmall pore specific (USP) UF (mL) post-transplantation, whereas the transport of small solutes (D/P creatinine) remains unchanged.
Individual values are given in Table 1. (B) RT–PCR demonstrating the expression of the GR (153 bp) in two peritoneal biopsies from patients on PD and
in the control human erythroleukaemia (HEL) cells. (C) Immunolocalization of the GR in human peritoneum. Double immunostaining with anti-
glucocorticoid receptor (a-GR) and anti-von Willebrand factor (a-vWF) antibodies show that the GR is expressed in endothelial cells lining the
capillaries and small vessels in the peritoneal membrane. Low magnification: bar: 50 lm; detail: 10 lm. m, mesothelium. (D) Organization of human
AQP1 gene promoter. The 3-kb proximal promoter of AQP1 is schematically represented, including the transcription start site and the 16 predicted GREs
(vertical symbols).
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Results and discussion
The evolution of the peritoneal transport parameters as as-
sessed by the mini-PET is shown on Table 1. As compared
with pre-transplantation, the post-transplantation peritoneal
equilibration test evidenced an ~2-fold increase in the
sodium sieving (and its surrogate marker the absolute dip
of dialysate sodium concentration) [11], paralleled by a sim-
ilar increase in the ultrasmall pore-specific UF. In contrast,
the small solute transport rate, as assessed by the D/P crea-
tinine and small pore-specific UF, was unchanged (Figure
1A, Table 1). By analogy with results obtained in the rat [9],
the potential role of AQP1 was substantiated by expression
studies demonstrating the expression of the GR in the capil-
lary endothelium of the human peritoneum and the ‘in silico’
identification of conserved GREs in the promoter of the
AQP1 gene (Figure 1B–D).
These data are the first to document a major increase in
the parameters of free water transport in PD patients fol-
lowing high-dose glucocorticoid administration in the con-
text of renal transplantation. To the best of our knowledge,
there are no previous reports on the effect of renal trans-
plantation per se on PD transport parameters. Several
points argue in favour of a specific effect of the glucocorti-
coids on AQP1. Firstly, the time course of the effect was
observed to be similar in the three patients who all had a
short course of uncomplicated PD followed by a living-
donor renal transplantation with immediate renal function.
Secondly, the fact that the changes are restricted to the very
parameters—sodium sieving, sodium dip and ultrasmall
pore-specific UF—that reflect the AQP1-mediated water
transport, whereas there is no effect on the D/P creatinine
parameter assessing small solute transport. The lack of ef-
fect of small solutes is important when considering that
exposure to mycophenolate mofetil can, at least in vitro,
inhibit angiogenesis [12, 13] and thus decrease the ex-
change area. Thirdly, the fact that no other external factor
other than high-dose glucocorticoids has been reported to
specifically affect free water transport and expression of
AQP1. Fourthly, we provide evidence for multiple GREs
in the promoter of the AQP1 gene and for a strong expres-
sion of the GR in the endothelium lining peritoneal capil-
laries, i.e. in the very cells where AQP1 mediates osmotic
water transport during PD. We fully acknowledge the lim-
itations of this preliminary report, including the small num-
ber of patients, with only one adult, which is not very
representative of the PD population, and the lack of low-
dose steroid controls assessing the effect of transplantation
(e.g. removing uremia, inducing acute changes in body
parameters and putting the peritoneal membrane at rest).
These limitations are balanced by the specificity of the
changes in free water transport and the lack of effect on
other transport parameters. We should also keep in mind
the possibility of a role for the interstitium in the water-only
fluid pathway [14], although the time course for a dramatic
reorganization of the interstitium (except for a reduction in
the degree of edema) seems to be too short for such an
explanation of the observed changes.
Conclusion
In conclusion, these data provide the first line of evidence
supporting the effect of corticosteroids on specific parameters
of AQP1-mediated water transport in PD patients. Although
these results have to be confirmed in a larger patient cohort,
the specificity of the changes in free water transport suggests
that pharmacologic induction of AQP1 may help to increase
water transport in patients treated by PD.
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